APG990’s Phase 1 trial showed a 60-day half-life, supporting three- and six-month dosing. Apogee plans a 2025 Phase 1b trial comparing APG279 to Dupixent in atopic dermatitis. Our government tra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback